[go: up one dir, main page]

WO2007028655A3 - Drug discovery for neurodevelopmental disorders and their complications - Google Patents

Drug discovery for neurodevelopmental disorders and their complications Download PDF

Info

Publication number
WO2007028655A3
WO2007028655A3 PCT/EP2006/008889 EP2006008889W WO2007028655A3 WO 2007028655 A3 WO2007028655 A3 WO 2007028655A3 EP 2006008889 W EP2006008889 W EP 2006008889W WO 2007028655 A3 WO2007028655 A3 WO 2007028655A3
Authority
WO
WIPO (PCT)
Prior art keywords
gamma
secretase
activity
cell line
organism
Prior art date
Application number
PCT/EP2006/008889
Other languages
French (fr)
Other versions
WO2007028655A2 (en
Inventor
Loo Karen Miriam Johanna Van
Gerardus Johannes Mari Martens
Original Assignee
Synthon Bv
Loo Karen Miriam Johanna Van
Gerardus Johannes Mari Martens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv, Loo Karen Miriam Johanna Van, Gerardus Johannes Mari Martens filed Critical Synthon Bv
Publication of WO2007028655A2 publication Critical patent/WO2007028655A2/en
Publication of WO2007028655A3 publication Critical patent/WO2007028655A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a method for identifying compounds which alter the activity of gamma-secretase, comprising provision of a collection of compounds; contacting the compounds of the collection with a cell line or organism expressing gamma-secretase; measurment of the gamma-secretase activity in the cell line or organism before and after the contact with the compound; and identification of the compounds in the collection that modulate the gamma-secretase activity of the cell line or organism. More in particular, the gamma-secretase that is expressed by the cell line or organism is a variant gamma-secretase, the activity of which is altered, in particular decreased, as compared to the gamma-secretase activity found in a human not carrying the SNP651 or carrying the wild- type Aph-lb gene.
PCT/EP2006/008889 2005-09-09 2006-09-08 Drug discovery for neurodevelopmental disorders and their complications WO2007028655A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP2005009853 2005-09-09
EPPCT/EP2005/009853 2005-09-09
EPPCT/EP2005/013055 2005-12-02
EPPCT/EP2005/013054 2005-12-02
EP2005013055 2005-12-02
EP2005013054 2005-12-02
EP2006003820 2006-04-25
EPPCT/EP2006/003820 2006-04-25

Publications (2)

Publication Number Publication Date
WO2007028655A2 WO2007028655A2 (en) 2007-03-15
WO2007028655A3 true WO2007028655A3 (en) 2007-05-03

Family

ID=37685825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008889 WO2007028655A2 (en) 2005-09-09 2006-09-08 Drug discovery for neurodevelopmental disorders and their complications

Country Status (1)

Country Link
WO (1) WO2007028655A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061673A2 (en) * 2006-11-24 2008-05-29 Synthon B.V. Drug discovery for cancer
WO2008061674A2 (en) * 2006-11-24 2008-05-29 Synthon B.V. Use of an animal model and method for testing drugs and treatments for cancer in humans
DE102017218522B3 (en) 2017-10-17 2018-12-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for gene-based diagnosis of dyslexia risk

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481987A1 (en) * 2003-05-26 2004-12-01 Aventis Pharma Deutschland GmbH Method for screening inhibitors of the gamma-secretase
WO2005063294A1 (en) * 2003-12-30 2005-07-14 Kowa Company, Ltd. Inhibitor for the formation of ϝ-secretase complex

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481987A1 (en) * 2003-05-26 2004-12-01 Aventis Pharma Deutschland GmbH Method for screening inhibitors of the gamma-secretase
WO2005063294A1 (en) * 2003-12-30 2005-07-14 Kowa Company, Ltd. Inhibitor for the formation of ϝ-secretase complex
EP1702626A1 (en) * 2003-12-30 2006-09-20 Kowa Company Ltd. Inhibitor for the formation of gammad-secretase complex

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HEBERT S S ET AL: "Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENCE, OXFORD, GB, vol. 17, no. 2, November 2004 (2004-11-01), pages 260 - 272, XP004592564, ISSN: 0969-9961 *
SAITO S ET AL: "Expression profiles of two human APH-1 genes and their roles in formation of presenilin complexes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 327, no. 1, 4 February 2005 (2005-02-04), pages 18 - 22, XP004697888, ISSN: 0006-291X *
SAITO S ET AL: "Identification and characterization of a novel human APH-1b splice variant lacking exon 4", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 330, no. 4, 20 May 2005 (2005-05-20), pages 1068 - 1072, XP004844838, ISSN: 0006-291X *
SHIROTANI KEIRO ET AL: "Identification of distinct gamma-secretase complexes with different APH-1 variants", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 40, 1 October 2004 (2004-10-01), pages 41340 - 41345, XP002418773, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2007028655A2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
EP2388322A4 (en) ENZYMATIC PREPARATION CONTAINING THERMOSTABLE DNA POLYMERASE, PROCESS FOR PRODUCING THE SAME, AND METHOD FOR DETECTING ANALYTE ORGANISM
WO2012061836A3 (en) Improved algorithm for detection of diabetes
WO2010118035A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
EA201100452A1 (en) TREATMENT OF INFLAMMATORY CONDITIONS
WO2008066330A8 (en) Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
WO2009145456A3 (en) Heterocyclic derivatives
WO2010101628A3 (en) Methods and products for in vivo enzyme profiling
WO2008135180A3 (en) Pet food and a process for its manufacture
WO2006026485A3 (en) Modulation of hif1-beta expression
WO2007028655A3 (en) Drug discovery for neurodevelopmental disorders and their complications
WO2011159050A3 (en) Method for differentiating human neural progenitor cells into dopaminergic neurons, and medium for differentiation thereof
WO2007134350A3 (en) Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases
WO2009089277A3 (en) Rel inhibitors and methods of use thereof
WO2009072608A1 (en) Gene capable of increasing the production of oil-and-fat in plant, and use thereof
EP2096165A4 (en) NOVEL ALCOHOL DEHYDROGENASE, GENE FOR ALCOHOL DEHYDROGENASE, VECTOR, TRANSFORMANT, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOL USING THE SAME
WO2005120642A3 (en) Tetrahydropyridothiophenes for treating hyperproliferative disorders
WO2010010211A3 (en) Disposable amperometric biosensor, production method thereof and method for determining the presence of analytes in foods
WO2009072609A1 (en) Gene capable of increasing the production of oil-and-fat in plant, and use thereof
WO2008009856A3 (en) Modulators of hsd17b7 in the treatment of acne or of hyperseborrhoea
WO2008012692A3 (en) Assay for efficacy of histone deacetylase inhibitors
WO2009008374A1 (en) Method for acquiring biological rhythm information
WO2009115165A3 (en) Cooling preparations for contact with human skin and/or mucous membranes, containing (1r,2s,5r)-2-isopropyl-5-methyl-n-(2-(pyridin-2-yl)ethyl-cyclohexane carboxamide and/or (1r,2s,5r)-n-(4-(cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06792010

Country of ref document: EP

Kind code of ref document: A2